Related Experiment Videos
Emerging biological therapies for pancreatic carcinoma
Andrew D Gilliam1, Susan A Watson
1Academic Unit of Cancer Studies, Department of Surgery Univertisy of Nottingham, Nottingham, NG7 2UH, UK. andrew.gilliam@nottingham.ac.uk
Aims:
The incidence of pancreatic carcinoma remains approximately equal to its mortality, with the vast majority of patients having advanced disease at presentation. This review is an update of the promising novel approaches involving biological therapy that may be used in conjunction with new chemotherapeutic agents in the near future.
Methods:
A literature review was performed using the National Library of Medicine's Pubmed database, combined with recently published data from the AGA and ASCO conferences.
Results:
Rapid progress is being made in gene and molecular technology potentially enabling us to inhibit pancreatic carcinogenesis and to reduce disease progression. Different targets include signal transduction inhibitors, gene therapy, genetic prodrug activation therapy, antisense therapy, immunotherapy, matrix metalloproteinase and cyclo-oxygenase-2 inhibition and hormonal manipulation.
Conclusion:
A variety of biological agents are currently undergoing clinical trials, targeting different areas of the pancreas'neoplastic process. .
Insights
Novel biological therapies show promise for treating pancreatic cancer, offering new hope alongside chemotherapy. These advanced treatments target specific molecular pathways to inhibit cancer growth and progression.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Pancreatic carcinoma has a high mortality rate, often diagnosed at advanced stages.
- Current treatment options have limited efficacy for widespread disease.
Purpose of the Study:
- To review emerging biological therapies for pancreatic cancer.
- To explore novel approaches in conjunction with chemotherapy.
Main Methods:
- Comprehensive literature review using PubMed.
- Inclusion of recent data from major oncology conferences (AGA, ASCO).
Main Results:
- Significant advancements in gene and molecular technologies.
- Identification of multiple therapeutic targets including signal transduction pathways, gene therapy, and immunotherapy.
- Emerging agents target matrix metalloproteinase and cyclo-oxygenase-2.
Conclusions:
- Various biological agents are in clinical trials for pancreatic cancer.
- These agents target distinct aspects of the neoplastic process.
- Future treatments may combine biological therapies with chemotherapy.